Bachrodt Amy 4

Accession 0002050422-25-000007

CIK 0001842295other

View on SEC.gov Company Profile

Filed

Dec 30, 7:00 PM ET

Accepted

Dec 31, 4:20 PM ET

Size

24.5 KB

Accession

0002050422-25-000007

Insider Transaction Report

Form 4

Period: 2025-12-29

Maze Therapeutics, Inc.MAZE

Bachrodt Amy

SVP, Finance

Transactions

Exercise/Conversion
Common Stock
2025-12-29$10.42/sh+124$1,292→ 13,089 total
Exercise/Conversion
Common Stock
2025-12-29$10.42/sh+9,876$102,908→ 22,965 total
Sale
Common Stock
2025-12-29$40.54/sh−9,400$381,071→ 13,565 total
Sale
Common Stock
2025-12-29$41.16/sh−600$24,695→ 12,965 total
Exercise/Conversion
Common Stock
2025-12-30$10.42/sh+2,395$24,956→ 15,360 total
Exercise/Conversion
Common Stock
2025-12-30$10.42/sh+2,605$27,144→ 17,965 total
Sale
Common Stock
2025-12-30$40.08/sh−5,000$200,407→ 12,965 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-12-29−124→ 2,396 total
Exercise: $10.42Exp: 2031-02-01→ Common Stock (124 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-12-29−9,876→ 23,834 total
Exercise: $10.42Exp: 2034-04-23→ Common Stock (9,876 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-12-30−2,395→ 1 total
Exercise: $10.42Exp: 2031-02-01→ Common Stock (2,395 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-12-30−2,605→ 2,581 total
Exercise: $10.42Exp: 2032-10-26→ Common Stock (2,605 underlying)

Footnotes (7)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.04 to $40.94 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $41.29 per share, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.36 per share, inclusive.
[F5]The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2025.
[F6]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
[F7]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Documents

1 file

4
form4-12312025_091203.xmlPrimary

Issuer

Maze Therapeutics, Inc.

CIK 0001842295

→

Entity typeother

Related Parties

filerCIK 0002050422

Filing Metadata

Form type: 4
Filed: Dec 30, 7:00 PM ET
Accepted: Dec 31, 4:20 PM ET
Size: 24.5 KB

View on SEC.gov